BioKier

Executive Summary

BioKier is a clinical-stage biotechnology company based in Cambridge, MA, developing oral small-molecule products designed to mimic the metabolic benefits of bariatric surgery for the management of lipids and glucose. Founded in 2018, the company leverages the 505(b)(2) regulatory pathway, which allows expedited approval by referencing existing safety and efficacy data. BioKier's lead candidates aim to improve gut hormone secretion and regulate glucose and lipid metabolism, offering a non-invasive alternative for patients with metabolic disorders such as type 2 diabetes and dyslipidemia. The company has already completed clinical trials demonstrating proof-of-concept, showing enhanced gut hormone responses and improved glycemic control.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 2 clinical trial for lead candidate70% success
• Q4 2026Announcement of additional clinical data from completed or ongoing studies80% success
• 2027Strategic partnership or licensing deal for commercialization50% success